Recombinant CCR2 (Plozalizumab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all CCR2 (Plozalizumab Biosimilar) products
- CCR2 (Plozalizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Mammalian Cells
- Expression System
- Mammalian cells
-
Clonality
- Monoclonal
-
Conjugate
- This CCR2 (Plozalizumab Biosimilar) antibody is un-conjugated
-
Application
- ELISA
- Purpose
- Plozalizumab Biosimilar - Anti-CCR2, CD192 mAb
- Characteristics
- Antibody Type: IgG1-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Grade
- Research Grade
- Isotype
- IgG1 kappa
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Storage
- -80 °C
- Storage Comment
- store at -80°C
-
- Target
- CCR2 (Plozalizumab Biosimilar)
- Abstract
- CCR2 (Plozalizumab Biosimilar) Products
- Target Type
- Biosimilar
- Background
-
MLN-1202,anti-CCR2,hu1D9
Plozalizumab is a humanized monoclonal antibody that targets CCR2 chemokine receptors found on the surface of white blood cells such as macrophages and monocytes. Plozalizumab has been investigated to treat Atherosclerosis. CCR2 is supposed to play an important role in the trafficking of monocytes and macrophages to sites of inflammation. - CAS-No
- 1610761-46-0
-
You are here:
